Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01506609
What this trial is testing

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 294
Post-approval studies (Phase 4)Active Not RecruitingNCT05457257
What this trial is testing

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 43
Not applicableStudy completedNCT00579007
What this trial is testing

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

Who this might be right for
Breast CancerOvarian Cancer
Memorial Sloan Kettering Cancer Center 224
Large-scale testing (Phase 3)UnknownNCT04296370
What this trial is testing

Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Who this might be right for
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd. 474
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07652073
What this trial is testing

DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Who this might be right for
Advanced or Metastatic Ovarian Cancer
Danatlas Pharmaceuticals Co., Ltd 30
Not applicableActive Not RecruitingNCT02653105
What this trial is testing

Women at Risk of Breast Cancer and OLFM4

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Institut Cancerologie de l'Ouest 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Early research (Phase 1)Active Not RecruitingNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Varun Monga, MBBS 13
Not applicableStudy completedNCT04222465
What this trial is testing

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients

Who this might be right for
Ovarian Neoplasms
AstraZeneca 207
Not applicableStudy completedNCT03684733
What this trial is testing

Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer

Who this might be right for
BRCA1 MutationBRCA2 MutationMammography+1 more
Royal Marsden NHS Foundation Trust 28
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Testing effectiveness (Phase 2)Ended earlyNCT03442556
What this trial is testing

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+7 more
University of Washington 18
Not applicableEnrolling By InvitationNCT06791161
What this trial is testing

Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Who this might be right for
Breast
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 300
Testing effectiveness (Phase 2)Study completedNCT03845296
What this trial is testing

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationLoss of Heterozygosity+8 more
SWOG Cancer Research Network 64
Very early researchEnded earlyNCT03382574
What this trial is testing

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Who this might be right for
Ovarian Carcinoma
National Cancer Institute (NCI) 2
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Study completedNCT01009788
What this trial is testing

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerBRCA1 Gene Mutation+1 more
Steven J Isakoff, MD, PhD 63
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Testing effectiveness (Phase 2)UnknownNCT05327621
What this trial is testing

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 50
Next Page